Tiffany, Kors to Re...
Health Care: Drugs
Bioline Rx Ltd. (BLRX: NASDAQ)
$1.63 -0.05 | -2.98%
05/24/13 - 03:59 PM ET
Latest Dividend:0.00
Latest Dividend Yield:0.00%
Dividend Ex-Date:12/31/69
Price Earnings Ratio:n/a
Price Earnings Comparisons:
| BLRX | Sector Avg. | S&P 500 |
|---|---|---|
| n/a | 0.00 | 17.70 |
Price Performance History (% change):
| 3 Mo | 1 Yr | 3 Yr |
|---|---|---|
| -54.47 | -37.55 | 0.00 |
| GROWTH | 12 Mo | 3 Yr | CAGR |
|---|---|---|---|
| Revenue | 0.00 | 0.00 | |
| Net Income | 0.00 | 0.00 | |
| EPS | 0.00 | 0.00 |
Earnings for BLRX:
| EBITDA | 0.00 |
| REVENUE | 0.00 |
Average Earnings Estimates
| Qtr (06/13) | Qtr (09/13) | FY (12/13) | FY (12/14) | |
|---|---|---|---|---|
| Average Estimate | $-0.02 | $-0.02 | $-0.07 | $0.08 |
| Number of Analysts | 1 | 1 | 1 | 1 |
| High Estimate | $-0.02 | $-0.02 | $-0.07 | $0.08 |
| Low Estimate | $-0.02 | $-0.02 | $-0.07 | $0.08 |
| Prior Year | $-0.02 | $-0.40 | $-1.20 | $-0.07 |
| Growth Rate (Year over Year) | 0.00% | 95.00% | 94.17% | 214.29% |
Portfolios with BLRX
- Portfolio NameUser Type
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Moving Hig...
Latest BLRX Headlines from TheStreet
- 5 Stocks Under $10 Set to Soar 04.18.13 | 02:04 pm
- BioLineRx Shares Fall On Schizophrenia Drug Failure 03.20.13 | 10:03 am
- 4 Stocks Under $5 Making Big Moves 02.22.13 | 03:02 pm
- BioLineRx: Tuesday's Hot Hep C Drug Stock 01.24.12 | 11:01 am
Press Releases for BLRX
- Oramed Pharmaceuticals Appoints New Chief Operating Officer And VP Of Business Development - PR Newswire 04.16.13 | 09:04 am
- BioLineRx Announces Results From Interim Analysis Of Phase II/III CLARITY Trial Of BL-1020 For Schizophrenia - Business Wire 03.20.13 | 09:03 am
- BioLineRx Receives Approval From French Regulatory Authorities To Commence A Phase I/II Clinical Trial For BL-8020, An Oral, Interferon-Free Treatment For Hepatitis C - Business Wire 03.13.13 | 07:03 am
- BioLineRx Reports Year End 2012 Financial Results - Business Wire 03.12.13 | 07:03 am
- BioLineRx's EDP-14, For Treatment Of Severe And Persistent Asthma, To Enter The Company's Main Therapeutic Pipeline As BL-9010 - Business Wire 02.28.13 | 07:02 am
- BioLineRx To Report Fourth Quarter And Year End 2012 Results On March 12, 2013 - Business Wire 02.26.13 | 07:02 am
- BioLineRx Announces Closing Of $8 Million Offering Of American Depositary Shares - Business Wire 02.13.13 | 07:02 am
- BioLineRx Announces Offering Of American Depositary Shares - Business Wire 02.06.13 | 09:02 am
- BioLineRx Provides Clarification Regarding Interim Analysis Of CLARITY Trial For BL-1020 - Business Wire 02.04.13 | 07:02 am
- BioLineRx To Present At The 2013 BIO CEO & Investor Conference In New York On February 12th - Business Wire 01.31.13 | 07:01 am
Partner Headlines for BLRX
- Morning Market Movers - Benzinga 10.03.12 | 09:10 am
- Healthcare Business Review: Vivus DISSED By Citron, Lundbeck, et al Have OPPORTUNITY - Wall St. Cheat Sheet 07.20.12 | 08:07 am
- Traders are Up and Actively Waving Hands for These 5 Stocks Today - Wall St. Cheat Sheet 06.05.12 | 01:06 pm
- Ultimate Market Recap: GM China Sales Soar, Apple Makes New Macs - Wall St. Cheat Sheet 06.05.12 | 09:06 am
- 5 High-Risk, High-Reward Biopharma Stocks - Seeking Alpha 02.14.12 | 09:02 am
- Company News for January 25, 2012 - Corporate Summary - Zacks 01.25.12 | 10:01 am
- Morning Market Movers - Benzinga 09.13.11 | 09:09 am
